Direct Thrombin Inhibitors
View Full Paper
Ask AI
Bookmark
Share
Key result
Direct thrombin inhibitors are effective alternatives to heparin for specific indications such as heparin-induced thrombocytopenia and percutaneous coronary intervention, but lack clear superiority for routine use in acute coronary syndromes or venous thromboembolism prophylaxis.
Population
Patients with heparin-induced thrombocytopenia, undergoing percutaneous coronary intervention, or requiring…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
DTI data are preliminary; leaves open optimal use and comparative effectiveness in cardiovascular settings.
Key Points
- The aim is to discuss the clinical applications and data concerning direct thrombin inhibitors, a new class of anticoagulants.
- Reviewed clinical data on FDA-approved direct thrombin inhibitors
- Discussed indications for hirudin, argatroban, bivalirudin, and desirudin
- Analyzed the use of DTIs in specific clinical situations such as heparin-induced thrombocytopenia and hip replacement.
- Hirudin and argatroban approved for heparin-induced thrombocytopenia
- Bivalirudin serves as an alternative anticoagulant during percutaneous coronary intervention
- Desirudin is effective in preventing venous thromboembolism in hip replacement patients.
Structured PICO
P
Population
A comprehensive review of patients requiring anticoagulation for the prevention and treatment of arterial and venous thrombosis, including acute coronary syndromes, atrial fibrillation, and orthopedic surgery.
I
Intervention
Parenteral direct thrombin inhibitors (hirudin, argatroban, bivalirudin, desirudin)
Direct thrombin inhibitors are a class of anticoagulants with specific FDA-approved indications including heparin-induced thrombocytopenia, percutaneous coronary intervention, and venous thromboembolism prophylaxis.
Limitations
- Lack of a specific antidote for rapidly reversing the anticoagulant effect of DTIs
- Hepatic toxicity concerns with long-term use of certain oral DTIs like ximelagatran
- The best method to monitor therapy with DTIs has not been clearly established
Cite This Study
Nisio et al. (2005) conducted a review in Arterial and venous thrombosis. Direct Thrombin Inhibitors (DTIs) vs. Heparins and Vitamin K antagonists was evaluated. Direct thrombin inhibitors are effective alternatives to heparin for specific indications such as heparin-induced thrombocytopenia and percutaneous coronary intervention, but lack clear superiority for routine use in acute coronary syndromes or venous thromboembolism prophylaxis.
View Full Paper
Ask AI
Bookmark
Share